Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine

Mark A. Jacobson; Donald I. Abrams; Paul A. Volberding; Peter Bacchetti; Judith Wilber; Richard E. Chaisson; Suzanne Crowe; Walter Howard; Andrew Moss

doi:10.1093/infdis/159.6.1029

Serum (3₂-microgiobulin decreases in patients with aids or arc treated with azidothymidine

Mark A. Jacobson, Donald I. Abrams, Paul A. Volberding, Peter Bacchetti, Judith Wilber, Richard E. Chaisson, Suzanne Crowe, Walter Howard, Andrew Moss

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

Abnormally elevated serum p₂-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p₂-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p₂-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p₂-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)₂-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p₂-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.

Original language	English (US)
Pages (from-to)	1029-1036
Number of pages	8
Journal	Journal of Infectious Diseases
Volume	159
Issue number	6
DOIs	https://doi.org/10.1093/infdis/159.6.1029
State	Published - Jun 1989
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/159.6.1029

Cite this

@article{d4bcb6e6ed7f42ef84a74429cb1e628c,

title = "Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine",

abstract = "Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.",

author = "Jacobson, {Mark A.} and Abrams, {Donald I.} and Volberding, {Paul A.} and Peter Bacchetti and Judith Wilber and Chaisson, {Richard E.} and Suzanne Crowe and Walter Howard and Andrew Moss",

note = "Funding Information: This work was supported in part by the State of California (allocated on the recommendation ofthe Universitywide Task Force on AIDS) and by contract AI-62541 with the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.",

year = "1989",

month = jun,

doi = "10.1093/infdis/159.6.1029",

language = "English (US)",

volume = "159",

pages = "1029--1036",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Serum (32-microgiobulin decreases in patients with aids or arc treated with azidothymidine

AU - Jacobson, Mark A.

AU - Abrams, Donald I.

AU - Volberding, Paul A.

AU - Bacchetti, Peter

AU - Wilber, Judith

AU - Chaisson, Richard E.

AU - Crowe, Suzanne

AU - Howard, Walter

AU - Moss, Andrew

N1 - Funding Information: This work was supported in part by the State of California (allocated on the recommendation ofthe Universitywide Task Force on AIDS) and by contract AI-62541 with the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

PY - 1989/6

Y1 - 1989/6

N2 - Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.

AB - Abnormally elevated serum p2-microglobulin has been associated with progression of human immunodeficiency virus (HIV) disease and could reflect in vivo HIV activity. We prospectively studied the effect of azidothymidine therapy on serum p2-microglobulin concentration in 41 patients with AIDS or AIDS-related complex. Median p2-microglobuIin concentration decreased from 4.02 mg/L before therapy to 3.73 mg/L at week 24 of therapy (P =.016). Individual changes in p2-microglobulin during azidothymidine therapy correlated with changes in serum HIV p24 antigen (Spearman, r =.42, P =.007). Also, in a randomized placebo-controlled study, median [)2-microglobulin concentration decreased after 16 w of therapy in 5 azidothymidine-treated patients compared with levels in 7 placebo-treated controls (P =.05). Serum p2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents.

UR - http://www.scopus.com/inward/record.url?scp=0024348488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024348488&partnerID=8YFLogxK

U2 - 10.1093/infdis/159.6.1029

DO - 10.1093/infdis/159.6.1029

M3 - Article

C2 - 2566637

AN - SCOPUS:0024348488

SN - 0022-1899

VL - 159

SP - 1029

EP - 1036

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 6

ER -

Serum (3₂-microgiobulin decreases in patients with aids or arc treated with azidothymidine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this